Prevention of cervical cancer through papillomavirus vaccination

Nature Reviews Immunology

Volumn 4, Issue 1, 2004, Pages 46-54

  Frazer, Ian H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; TUMOR ANTIGEN; VIRUS VACCINE;

CANCER IMMUNOTHERAPY; CANCER PREVENTION; DISEASE ASSOCIATION; GENOTYPE; HUMAN; INFECTION CONTROL; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; UTERINE CERVIX CARCINOMA; VACCINATION; VERRUCA VULGARIS; VIRUS PARTICLE; WART VIRUS;

EID: 0345827680     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1260     Document Type: Review

References (86)

1. Koutsky, L. A. et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651 (2002). The first randomized placebo-controlled trial of the efficacy of a virus-like particle (VLP)-based vaccine in preventing infection with a 'high-risk' human papillomavirus (HPV), showing 100% efficacy at preventing persistent HPV infection in young, previously uninfected women.
2. Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J. & Shah, K. V. The causal relation between human papillomavirus and cervical cancer. J. Clin Pathol. 55, 244-265 (2002).
3. Chang, M. H. et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 284, 3040-3042 (2000).
4. Zur Hausen, H., de Villiers, E. M. & Gissmann, L. Papillomavirus infections and human genital cancer. Gynecol. Oncol. 12, S124-S128 (1981).
5. Zur Hausen, H. Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. Semin. Cancer Biol. 9, 405-411 (1999).
6. Muñoz, N. et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348, 518-527 (2003).
7. Schlecht, N. F. et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J. Natl Cancer Inst. 95, 1336-1343 (2003).
8. Goldie, S. J. et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int. J. Cancer 106, 896-904 (2003).
9. Sillman, F. H., Sentovich, S. & Shaffer, D. Ano-genital neoplasia in renal transplant patients. Ann. Transplant. 2, 59-66 (1997).
10. Ferenczy, A., Coutlee, F., Franco, E. & Hankins, C. Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments CMAJ 169, 431-434 (2003).
11. Frazer, I. H. Immunology of papillomavirus infection. Curr. Opin. Immunol. 8, 484-491 (1996).
12. Tindle, R. W. Immune evasion in human papillomavirus-associated cervical cancer. Nature Rev. Cancer 2, 59-65 (2002).
13. Matthews, K. et al. Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated downregulation of E-cadherin. J. Virol. 77, 8378-8385 (2003).
14. Tay, S. K., Jenkins, D., Maddox, P., Campion, M. & Singer, A. Subpopulations of Langerhans cells in cervical neoplasia. Br. J. Obstet. Gynaecol. 94, 10-15 (1987).
15. Ronco, L. V., Karpova, A. Y., Vidal, M. & Howley, P. M. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12, 2061-2072 (1998).
16. Barnard, P. & McMillan, N. A. J. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-α. Virology 259, 305-313 (1999).
17. Park, J. S. et al. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J. Biol. Chem. 275, 6764-6769 (2000).
18. Nees, M. et al. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-κB-responsive genes in cervical keratinocytes. J. Virol. 75, 4283-4296 (2001).
19. Campo, M. S. Animal models of papillomavirus pathogenesis. Virus Res. 89, 249-261 (2002).
20. Carter, J. J. et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis. 181, 1911-1919 (2000). A longitudinal cohort study defining the slow and incomplete acquisition of antibody specific for HPV-encoded capsid proteins and relating time of seroconversion to the onset of HPV infection.
21. Jochmus-Kudielka, I. et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: Correlation of anti-E7 reactivity with cervical cancer. J. Natl Cancer Inst. 81, 1698-1704 (1989). A cross-sectional study defining the prevalence of antibody to viral non-structural proteins in patients with invasive cervical cancer.
22. Campo, M. S. Animal models of papillomavirus pathogenesis. Virus Res. 89, 249-261 (2002).
23. Jarrett, W. F. et al. Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types. Vet. Rec. 126, 473-475 (1990).
24. Lin, Y. L., Borenstein, L. A., Selvakumar, R., Ahmed, R. & Wettstein, F. O. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 187, 612-619 (1992).
25. Ghim, S. et al. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus. Exp. Mol. Pathol. 68, 147-151 (2000).
26. + lymphocytes. Virology 283, 31-39 (2001).
27. Arany, I. et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res. 43, 55-63 (1999).
28. Kadish, A. S. et al. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol. Biomarkers Prev. 11, 483-488 (2002).
29. Welters, M. J. P. et al. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res. 63, 636-641 (2003).
30. Höpfl, R. et al. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 356, 1985-1986 (2000). A study showing a link between cell-mediated immunity to HPV non-structural proteins and regression of HPV-associated premalignant changes in the cervix.
31. Jarrett, W. F. et al. Studies on vaccination against papillomaviruses: a comparison of purified virus, tumour extract and transformed cells in prophylactic vaccination. Vet. Rec. 126, 449-452 (1990).
32. Zhou, J., Liu, W. J., Peng, S. W., Sun, X. Y. & Frazer, I. H. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J. Virol. 73, 4972-4982 (1999).
33. Collier, B., Öberg, D., Zhao, X. M. & Schwartz, S. Specific inactivation of inhibitory sequences in the 5′ end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells. J. Virol. 76, 2739-2752 (2002).
34. Frattini, M. G., Lim, H. B. & Laimins, L. A. In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression. Proc. Natl Acad, Sci. USA 93, 3062-3067 (1996).
35. Zhao, K. N. & Frazer, J. H. Replication of bovine papillomavirus type 1 (BPV-1) DNA in Sacccharomyces cerevisiae following infection with BPV-1 virions. J. Virol. 76, 3359-3364 (2002).
36. Zhou, J., Sun, X. Y., Stenzel, D. J. & Frazer, I. H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185, 251-257 (1991). The first of a series of studies showing that expression of the HPV16 L1 capsid protein by eukaryotic cells from the second ATG initiation codon of the gene allows assembly of HPV VLPs.
37. Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R. & Schiller, J. T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl Acad. Sci. USA 89, 12180-12184 (1992).
38. Chen, X. J. S., Garcea, R. L., Goldberg, I., Casini, G. & Hamson, S. C. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol. Cell 5, 557-567 (2000).
39. Bell, J. A. et al. A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. Pathobiology 62, 194-198 (1994).
40. Billich, A. HPV vaccine MedImmune/GlaxoSmithKline. Curr: Curr. Opin. Investig. Drugs 4, 210-213 (2003).
41. Nardelli-Haefliger, D. et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J. Natl. Cancer Inst. 95, 1128-1137 (2003).
42. Giroglou, T. et al. Immunological analyses of human papillomavirus capsids. Vaccine 19, 1783-1793 (2001).
43. Smyth, M. J., Godfrey, D. I. & Trapani, J. A. A fresh look at tumor immunosurveillance and immunotherapy. Nature Immunol. 2, 293-299 (2001).
44. Peh, W. L. et al. Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J. Virol. 76, 10401-10416 (2002).
45. Han, R., Breitburd, F., Marche, P. N. & Orth, G. Linkage of regression and malignant conversion of rabbit viral papillomas to MHC class II genes. Nature 356, 66-68 (1992).
46. Wang, S. S. et al. Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J. Infect. Dis. 184, 1310-1314 (2001)
47. Han, R. et al. DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits. J. Virol. 74, 9712-9716 (2000). Evidence using the best available animal model of HPV-associated malignancy that specific immunotherapy can alter the outcome of HPV infection.
48. Stanley, M. A. Progress in prophylactic and therapeutic vaccines for human papillomavirus infection. Expert Rev. Vaccines 2, 381-389 (2003)
49. Chen, C. H. et al. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther. 6, 1972-1981 (1999).
50. Ji, H. X. et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum. Gene Ther. 10, 2727-2740 (1999).
51. Ji, H. X. et al. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int. J. Cancer 78, 41-45 (1998).
52. + T-cell responses that home to the tumor site. J. Virol 75, 9654-9664 (2001).
53. Velders, M. P. et al. Eradication of established tumors by vaccination with venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res. 61, 7861-7867 (2001).
54. Gunn, G. R. et al. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol. 167, 6471-6479 (2001).
55. Gerard, C. M. et al. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 19, 2583-2589 (2001).
56. Zwaveling, S. et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169, 350-358 (2002).
57. Chu, N. R. et al. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol. 121, 216-225 (2000).
58. Hariharan, K. et al. Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. Int. J. Oncol. 12, 1229-1235 (1998).
59. Indrova, M. et al. Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines: in vitro priming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide. Int. J. Mol. Med. 7, 97-100 (2001).
60. Stewart, T. J., Smyth, M. J., Fernando, G. J., Frazer, I. H. & Leggatt, G. R. Inhibition of early tumor growth requires Jα18-positive (natural killer T) cells. Cancer Res. 63, 3058-3060 (2003). A paper showing that transplantable tumour models of immunotherapy of cancer in animals are susceptible to different types of immunotherapy, according to the maturity of the tumour.
61. + cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. J. Immunol. 161, 2421-2427 (1998).
62. + T cell to a fully functional tumor killer cell. Cancer Res. 62, 6438-6441 (2002).
63. Dunn, L. A. et al. Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. Virology 235, 94-103 (1997).
64. Azukizawa, H. et al. Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes. Eur. J. Immunol. 33, 1879-1888 (2003).
65. Frazer, I. H. et al. Tolerance or immunity to a tumor antigen expressed in somatic cells can be determined by systemic proinflammatory signals at the time of first antigen exposure. J. Immunol. 167, 6180-6187 (2001).
66. Leggatt, G. R., Dunn, L. A., De Kluyver, R., Stewart, T. & Frazer, I. H. Interferon-γ enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide. Immunol. Cell Biol. 80, 415-424 (2002).
67. Brady, C. S. et al. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 55, 401-411 (2000).
68. Evans, M. et al. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J. Immunol. 167, 5420-5428 (2001). This paper provides evidence that cervical cancer cells are selected for poor presentation of HPV-encoded antigens to the immune system.
69. + T cell IFNγ response to a novel viral epitope in a primed host. J. Immunol. 171, 4765-4772 (2003).
70. Pascual, D. W., Walters, N. & Hillemeyer, P. Repeated intratracheal instillations of nonreplicating adenovirus 2 vector attenuate CTL responses and IFN-γ production. J. Immunol. 160, 4465-4472 (1998).
71. Tindle, R. W. Immune evasion in human papillomavirus-associated cervical cancer. Nature Rev. Cancer 2, 59-65 (2002).
72. Connor, M. E. & Stern, P. L. Loss of MHC class 1 expression in cervical carcinomas. Int. J. Cancer 46, 1029-1034 (1990).
73. Fowler, N. & Frazer, I. H. Mutations in TAP genes are common in cervical carcinomas. Gynaecol. Oncology (In the press).
74. De Jong, A. et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20, 3456-3464 (2002).
75. Goldstone, S. E., Palefsky, J. M., Winnett, M. T. & Neefe, J. R. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis. Colon Rectum 45, 502-507 (2002).
76. Klencke, B. et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin. Cancer Res. 8, 1028-1037 (2002).
77. Sheets, E. E. et al. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am. J. Obstet. Gynecol. 188, 916-926 (2003).
78. Borysiewicz, L. K. et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347, 1523-1527 (1996).
79. Davidson, E. J. et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res. 63, 6032-6041 (2003).
80. Baldwin, P. J. et al. Vaccinia-expressed human papillomavirus 16 and 18 E6 and E7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin. Cancer Res. 9, 5205-5213 (2003). References 79 and 80 show that development of immunity to HPV non-structural proteins after administration of vaccinia virus recombinant for the viral proteins to patients with HPV-associated anogenital malignancy is associated with partial resolution of disease.
81. Van Driel, W. J. et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer 35, 946-952 (1999).
82. Frazer, I. H. et al. In Vaccines for Human Papillomavirus Infection and Anogenital Disease. (ed. Tindle, R. W.) 91-104 (Landes Bioscience, Austin, Texas, 1999).
83. Muderspach, L. et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. 6, 3406-3416 (2000).
84. Zhang, L. F. et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 18, 1051-1058 (2000).
85. Ferrara, A. et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J. Cancer Res. Clin. Oncol. 129, 521-530 (2003).
86. Frazer, I. H et al. Immunotherapy for HPV associated pre-cancer Cancer Immunity 3, Suppl. 1, 25 (2003).